INTRODUCTION AND OBJECTIVES: Treatment options for renal calculi are well established for smaller stones (<10mm), and larger stones (>20mm). Smaller stones are often treated with surveillance, shockwave lithotripsy, or flexible ureteroscopy (URS) while calculi larger than 20 mm are typically treated with percutaneous nephrolithotripsy (PCNL). Treatment guidelines for renal calculi in the transition zone with stone sizes that approach 20 mm are not as well defined. The objective of this study was to compare ureteroscopic laser lithotripsy to PCNL for the treatment of renal calculi measuring 15-20 mm and to determine which of these two would be the preferred treatment considering cost and patient preferences (utilities).
INTRODUCTION AND OBJECTIVES: Treatment options for renal calculi are well established for smaller stones (<10mm), and larger stones (>20mm). Smaller stones are often treated with surveillance, shockwave lithotripsy, or flexible ureteroscopy (URS) while calculi larger than 20 mm are typically treated with percutaneous nephrolithotripsy (PCNL). Treatment guidelines for renal calculi in the transition zone with stone sizes that approach 20 mm are not as well defined. The objective of this study was to compare ureteroscopic laser lithotripsy to PCNL for the treatment of renal calculi measuring 15-20 mm and to determine which of these two would be the preferred treatment considering cost and patient preferences (utilities).
METHODS: The cost and utilities of URS and PCNL were compared for the treatment of 15-20 mm renal calculi using a cost-utility decision analysis model. Probability estimates were derived from the literature. Direct third-party payer costs were determined in Canadian dollars and obtained from Data Integration and Management Repository (DIMR) of Alberta Health Services and the Schedule of Medical Benefits, Alberta Health and Wellness. There is a paucity of previously reported measured health utilities for the treatment of nephrolithiasis, therefore, preferences were measured by proxy via an expert panel using the validated EQ-5D health status instrument. The decision analysis model was created and then run using TreeAge Pro software. RESULTS: The model predicted URS and laser lithotripsy ($6356 per patient with utility [ 0.75) to dominate PCNL ($10,244 per patient with utility [ 0.77) with a cost/utility ratio of $8475 for URS compared $13,304 for PCNL. This yields an incremental cost-savings of $4829 per patient favoring the URS strategy. The validity of the model was tested with sensitivity analysis.
CONCLUSIONS: From an economic perspective, this model predicts that ureteroscopic laser lithotripsy should be used over PCNL for the treatment of most renal calculi measuring 15-20 mm. However, the model also predicts that overall patient preference/utility is similar for both treatments with PCNL having a slightly better estimated patient preference.
Source of Funding: None

MP08-19 BEYOND PREVALENCE: INCIDENCE RATES OF KIDNEY STONES IN THE UNITED STATES
Gina Tundo*, Annah Vollstedt, Lebanon, NH; William Meeks, Linthicum, MD; Vernon Pais, Lebanon, NH INTRODUCTION AND OBJECTIVES: It is well documented that the prevalence of nephrolithiasis is increasing in adults in the United States over time. Approximately 11% of men and 7% of women have reported a lifetime history of nephrolithiasis in cross-sectional studies. However, the burden of acute management of stone disease may be better assessed from annual incidence rates. This accounting of new stone events, however, is not as well described or understood.
METHODS: The Medical Expenditure Panel Survey is a set of large-scale, healthcare utilization surveys of families, individuals, their healthcare providers, and employers, with surveys administered every 6 months for the duration of each individual's 2-year panel. We queried the survey data of adult participants between 2005 and 2015, with analysis conducted with provided weights and strata to allow our findings to be representative of the civilian non-institutionalized US adult population. Those with diagnosed renal or ureteral calculi as noted by ICD-9 codes were included as our incident stone formers.
RESULTS: In 2005, the mean age of stone formers was 45 years. 52.2% of stone formers were male, 91% white, and 47.6% were residing in the Southern US. The incidence of stone occurrences was 0.6% (177/33,961 individuals, weighted to represent population of 1,923,322/296,185,002 individuals).
By 2015, the mean age was 51.7 years, with 52% male, 83% white, and 38.2% residing in the Southern US. The overall incidence increased to 0.9% in 2015 (247/35,427 individuals, weighted to represent population of 2,810,497/321,423,251 individuals). This increase in incidence between 2005 and 2015 was statistically significant with a p-value of <0.01.
CONCLUSIONS: In this large-scale, nationally-representative analysis of adults in the United States, the incidence of stone occurrence annually is less than 1%. Nonetheless, incidence rates do appear to be increasing over time, rising from 0.6% in 2005 to 0.9% in 2015. This data may help to better anticipate need for urologic care for stone disease and may help direct resource distribution.
Source of Funding: AUA Data Grant
MP08-20 AN EVALUATION OF MULTIPLE-DRUG RESISTANCE (MDR) BACTERIA IN PATIENTS WITH URINARY STONE DISEASE: DATA FROM A HIGH-VOLUME STONE MANAGEMENT CENTER
Shu Wang*, Baltimore, MD; Yitian Zhang, Chapel Hill, NC; Xin Zhang, Jianxing Li, Beijing, China, People's Republic of INTRODUCTION AND OBJECTIVES: MDR bacteria can lead to intractable infection in patients with urolithiasis and increase mortality rate as well as medical costs. Thus it is important for clinicians to establish evidence-based strategies of antibiotics use. This study aims to evaluate the prevalence of MDR bacteria in a high volume stone management center and investigate the resistance patterns.
METHODS: A retrospective study was performed among patients diagnosed with urolithiasis in Beijing Tsinghua Changgung Hospital from 2014 December to 2018 May. Only patients who had positive urinary culture with a bacteria growth >10^5 colony-forming units and drug-sensitivity tests were included. MDR bacteria were defined as any bacteria that gain resistance to at least one agent in !3 classes of antibiotics.
RESULTS: 1655 patients with urolithiasis were analyzed, among which 357 patients had positive urinary culture results, yielding 457 isolates of 45 kinds. The E.coli remains the most common with a prevalence of 29.3%, followed by E.faecalis (12.0%), P.mirabilis (10.5%), K.pneumonia (6.8%),and S.agalactiae (4.8%). 44.4% isolates were identified as MDR. The most 3 common G-bacteria were E.coli, P.mirabilis, and K.pneumonia, with a MDR rate of 84.33%, 62.5%, and 48.39%, respectively. The most 3 common Gþ bacteria were E.faecalis, S.agalactiae, and E.faecium, with a MDR rate of 0, 54.55%, and 0, respectively. As for the most 3 common G-bacteria, drug-resistance rates were different between MDR and non-MDR in Ampicillin, Ampicillin/sulbactam, Cefozolin, Ceftriaxone, Ceftazidime, Cefepime, Gentamicin, Amikacin, Ciprofloxacin, and Levofloxacin, while there were no significant differences among the drug-resistance rates in Piperacillin/tazobactam, Cefperazone/Sulbactam, and Carbapenems. Antibiotics combined with beta-lactamase inhibitors achieved lower drug-resistance rates in both MDR and non-MDR group(p<0.001).
CONCLUSIONS: MDR bacteria were common among patients with urolithiasis, achieving high drug-resistance rates of Ampicillin, firstgeneration and part of third-generation cephalosporins, and fluoroquinolones.
Antibiotics with beta-lactamase inhibitors, carbapenems, and amikacin proved to be effective for MDR bacteria.
